1. Ikemura N, Kohsaka S, Kimura T, et al. Assessment of Sex Differences in the Initial Symptom Burden, Applied Treatment Strategy, and Quality of Life in Japanese Patients With Atrial Fibrillation. JAMA network open. 2019;2(3):e191145. doi:10.1001/jamanetworkopen.2019.1145
2. Samaras A, Kartas A, Akrivos E, et al. A novel prognostic tool to predict mortality in patients with atrial fibrillation: The BASIC-AF risk score. Hellenic journal of cardiology: HJC = Hellenike kardiologike epitheorese. Published online January 29, 2021. doi:10.1016/j.hjc.2021.01.007
3. Khamis RY, Ammari T, Mikhail GW. Gender differences in coronary heart disease. Heart. 2016;102(14):1142-1149. doi:10.1136/heartjnl-2014-306463
4. Song J-J, Ma Z, Wang J, Chen L-X, Zhong J-C. Gender Differences in Hypertension. Journal of Cardiovascular Translational Research. 2019;13(1):47-54. doi:10.1007/s12265-019-09888-z
5. Bozkurt B, Khalaf S. Heart Failure in Women. Methodist DeBakey cardiovascular journal. 2017;13(4):216-223. doi:10.14797/mdcj-13-4-216
6. Mohanty S, Trivedi C, Gianni C, Natale A. Gender specific considerations in atrial fibrillation treatment: a review. Expert Opinion on Pharmacotherapy. 2018;19(4):365–374. doi:10.1080/14656566.2018.1434144
7. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nature Reviews Cardiology. 2016;13(6):321-332. doi:10.1038/nrcardio.2016.45
8. Tzikas A, Samaras A, Kartas A, et al. Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial. European Heart Journal Cardiovascular Pharmacotherapy. 2020;(32339234). doi:10.1093/ehjcvp/pvaa039
9. Samaras A, Kartas A, Vasdeki D, et al. Rationale and design of a randomized study comparing Motivational Interviewing to Support Oral Anticoagulation adherence versus usual care in patients with nonvalvular atrial fibrillation: The MISOAC-AF trial. Hellenic journal of cardiology: HJC = Hellenike kardiologike epitheorese. Published online April 4, 2020. doi:10.1016/j.hjc.2020.02.007
10. World Medical Association. World Medical Association Declaration of Helsinki. JAMA. 2013;310(20):2191. doi:10.1001/jama.2013.281053
11. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210
12. Anselmino M, Battaglia A, Gallo C, et al. Atrial fibrillation and female sex. Journal of Cardiovascular Medicine (Hagerstown, Md). 2015;16(12):795–801. doi:10.2459/JCM.0000000000000239
13. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. Journal of the American College of Cardiology. 2007;49(5):572–577. doi:10.1016/j.jacc.2006.10.047
14. Piccini JP, Simon DN, Steinberg BA, et al. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. JAMA cardiology. 2016;1(3):282–291. doi:10.1001/jamacardio.2016.0529
15. Kavousi M. Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. Frontiers in Cardiovascular Medicine. 2020;7(32118043):3. doi:10.3389/fcvm.2020.00003
16. Lip GYH, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circulation Cardiovascular Quality and Outcomes. 2015;8(2 Suppl 1):S12–20. doi:10.1161/CIRCOUTCOMES.114.001556
17. Lip GYH, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. 2015;17(1):24–31. doi:10.1093/europace/euu155
18. Kartas A, Samaras A, Vasdeki D, et al. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge. Journal of Cardiovascular Pharmacology and Therapeutics. 2019;24(3):225-232. doi:10.1177/1074248418821712
19. Andrade JG, Deyell MW, Lee AYK, Macle L. Sex Differences in Atrial Fibrillation. Canadian Journal of Cardiology. 2018;34(4):429-436. doi:10.1016/j.cjca.2017.11.022
20. ElMaghawry M. ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation. Global Cardiology Science and Practice. 2015;2015(3):35. doi:10.5339/gcsp.2015.35
21. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. European Heart Journal. 2013;34(20):1481–1488. doi:10.1093/eurheartj/ehs348
22. Hohnloser SH, Kuck K-H, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. The Lancet. 2000;356(9244):1789-1794. doi:10.1016/s0140-6736(00)03230-x
23. Rienstra, Michiel, et al. “Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation.” JACC: Heart Failure, vol. 1, no. 1, Feb. 2013, pp. 21–28, 10.1016/j.jchf.2012.09.002. Accessed 27 Apr. 2021.
24. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. Journal of the American College of Cardiology. 2005;46(7):1298–1306. doi:10.1016/j.jacc.2005.05.078
25. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England journal of medicine. 2002;347(23):1825-1833. doi:10.1056/NEJMoa021328
26. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590-2597. doi:10.1001/jama.270.21.2590
27. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: Ten years later. Gender Medicine Official Journal of the Partnership for Gender-Specific Medicine at Columbia University. 2010;7(3):206-217. doi:10.1016/j.genm.2010.06.001
28. Roy D, Talajic M, Nattel S, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. New England Journal of Medicine. 2008;358(25):2667-2677. doi:10.1056/nejmoa0708789
29. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Archives of Internal Medicine. 2012;172(13):997–1004. doi:10.1001/archinternmed.2012.2266
30. Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation. Circulation. 2012;126(23):2680-2687. doi:10.1161/circulationaha.112.092494
31. de Denus S. Rate vs Rhythm Control in Patients With Atrial Fibrillation. Archives of Internal Medicine. 2005;165(3):258. doi:10.1001/archinte.165.3.258
32. Page RL, Connolly SJ, Crijns HJGM, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). The American Journal of Cardiology. 2011;107(7):1019–1022. doi:10.1016/j.amjcard.2010.11.02